LEGISLATURE OF THE STATE OF IDAHO
Sixty-eighth Legislature First Regular Session - 2025
IN THE HOUSE OF REPRESENTATIVES
HOUSE BILL NO. 385
BY HEALTH AND WELFARE COMMITTEE
1 AN ACT
2 RELATING TO PRESCRIPTION DRUGS; AMENDING CHAPTER 17, TITLE 54, IDAHO CODE,
3 BY THE ADDITION OF A NEW SECTION 54-1740, IDAHO CODE, TO ESTABLISH PRO-
4 VISIONS REGARDING CERTAIN PROHIBITED ACTIONS BY PHARMACEUTICAL MANU-
5 FACTURERS; AND DECLARING AN EMERGENCY AND PROVIDING AN EFFECTIVE DATE.
6 Be It Enacted by the Legislature of the State of Idaho:
7 SECTION 1. That Chapter 17, Title 54, Idaho Code, be, and the same is
8 hereby amended by the addition thereto of a NEW SECTION, to be known and des-
9 ignated as Section 54-1740, Idaho Code, and to read as follows:
10 54-1740. AFFORDABLE ACCESS TO PRESCRIPTION DRUGS. (1) As used in this
11 section:
12 (a) "340B drug" means a covered outpatient drug under 42 U.S.C. 256b(b)
13 that has been subject to an offer for reduced prices by a pharmaceutical
14 manufacturer under 42 U.S.C. 256b(a)(1).
15 (b) "Contract pharmacy" means a pharmacy that is registered with the
16 340B office of pharmacy affairs information system, or a successor sys-
17 tem, under contract with a covered entity, and authorized under such
18 contract to receive and dispense 340B drugs on behalf of the covered en-
19 tity.
20 (c) "Covered entity" means a covered entity as defined in 42 U.S.C.
21 256b(a)(4) participating or authorized to participate in the federal
22 340B drug pricing program pursuant to 42 U.S.C. 256b.
23 (d) "Pharmaceutical manufacturer" means an entity, agent, or affiliate
24 of such an entity that manufactures drugs, biologics, or other pharma-
25 ceutical products.
26 (e) "Pharmacy" means any place located within this state where drugs
27 are dispensed and pharmacy services are provided and any place outside
28 of this state where drugs are dispensed and pharmacy services are pro-
29 vided to residents who are physically located in this state.
30 (2) A pharmaceutical manufacturer shall not deny, restrict, prohibit,
31 or otherwise interfere with, either directly or indirectly, the acquisition
32 of a 340B drug by or delivery of a 340B drug to a contract pharmacy on behalf
33 of a covered entity.
34 (3) A pharmaceutical manufacturer shall not interfere with or other-
35 wise restrict a pharmacy contract between a covered entity and any contract
36 pharmacy.
37 (4) A pharmaceutical manufacturer shall not, either directly or indi-
38 rectly, require a covered entity or contract pharmacy to submit, validate,
39 certify, or provide any claims, utilization, purchasing, or other data as
40 a condition for allowing the acquisition of a 340B drug by or delivery of a
41 340B drug to a covered entity or contract pharmacy. This prohibition does
42 not include pharmaceutical manufacturer audits that pertain directly to a

2
1 covered entity's compliance with 42 U.S.C. 256b(a)(5)(A)(i) or 42 U.S.C.
2 256b(a)(5)(B) conducted in accordance with procedures established by the
3 secretary of the department of health and human services.
4 (5) Nothing in this section shall be construed or applied to be less re-
5 strictive than applicable federal law for a person or entity regulated by
6 this section. Nothing in this section shall be construed or applied to be in
7 conflict with applicable federal law and related regulations or other laws
8 of this state if the state law is compatible with applicable federal law.
9 Limited distribution of a drug required under 21 U.S.C. 355-1 shall not be
10 construed as a violation of this section.
11 (6) The provisions of this section are hereby declared to be severable
12 and if any provision of this section or the application of such provision to
13 any person or circumstance is declared invalid for any reason, such declara-
14 tion shall not affect the validity of the remaining portions of this section.
15 (7) If the 340B drug pricing program described in 42 CFR 10 is elim-
16 inated at the federal level, then the provisions of this section shall be
17 null, void, and of no force and effect.
18 SECTION 2. An emergency existing therefor, which emergency is hereby
19 declared to exist, this act shall be in full force and effect on and after
20 July 1, 2025.

[DELETED: EOFTESEOFIhLeFtRrSn-2NTEHEOFREBLN.3YHHADWECNAGTOPND;AGCR1,TE5,IOCYTEANOFANWSN5,IOC,TOEHPSRGCNPDASBYPLM;ADDGANEYADPGANEEDeItEdbyteLeofteSeofIN1.TtCr1,Te5,IoC,b,adteseiyadbyteantoofaNWS,tobeknadddasSn5,IoC,adtordasf.AEASTOPND.()Asudint)"Bd"msacdotdgur42U.2thsbnsttoanorfrrdpsbyaprur42U.2)"tp"msapyttisrdwhtBoeofpyasins,orasrs,urctwhacde,adadursttoreadde3Bdsonbfoftecde)"de"msacdeyasddin42U)pgoradtopeintefBdgpgpmptto42U.2)"lm"msane,a,orafshaneyttmsd,b,ororplp)""msaypeldwntssewededdadpyssaepdadaypeoftssewedsaeddadpyssaepdtorswoaepyldintss)Aplmrslntd,r,proeiew,erdyori,teafa3Bdgbyordyofa3Bdgtoactpyonbfacde)Aplmrslntiewhoroertapyctbnacdeyadayc)Aplmrsln,erdyori,reacdeyorctpytos,v,orpeayc,u,p,orordaacnfragteanofa3BdgbyordyofBdgtoacdeyorctp.Tspndtieplmrasttpndyto]
[DELETED: descewh42U.2)or42U)cdinaewhpsedbytyoftedtofhhadhns)Ngintssnslbecdoradtobelsretnaefllwfrapnoreyrdbss.Ngintssnslbecdoradtobeitwhaefllwadrdrsororlftsseifteselwiscewhaefllddnofadgrdur21U.31slntbdasavnoftss)Tepsoftssnaehyddtobesdifaypnoftssnorteanofshpntypnorceisddidfrayr,shdnslntattevyoftergpsoftss)Ifte3Bdgpgpmddin42CR10isedattefll,tntepsoftssnslb,v,adofnofeadeN2.Aneyegt,wheyishdtoe,tsatslbeinflfeadetonaday1,2]